Liberta Co., Ltd. (4935) AI Stock Analysis

• Market Cap: ¥9.77B
• Dividend Yield: 0.48%
• Average Volume (3M): 77.87K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.19
• Revenue Growth: 10.13%
• EPS Growth: -14654.18%
• Country: JP
• Employees: 128
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): 0.41
• Shares Outstanding: 30,262,600
• 10 Day Avg. Volume: 36,500
• 30 Day Avg. Volume: 77,873
• PEG Ratio: 2.23
• Price to Book (P/B): 3.56
• Price to Sales (P/S): 0.65
• P/FCF Ratio: -8.96
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: ¥333.00 ▼(-82.24% Downside)

Liberta Co., Ltd.'s overall stock score is primarily impacted by financial performance challenges, including profitability and cash flow issues. Technical analysis indicates bearish momentum, and valuation metrics are unfavorable due to a negative P/E ratio. The lack of earnings call and corporate events data limits further insights.

Positive Factors

Sustained Revenue Growth

Double-digit revenue growth year-over-year indicates durable demand for Liberta's product portfolio and successful distribution reach. Sustained top-line expansion can support scale benefits, fund R&D and marketing, and provide a runway to restore profitability if margins and cost control improve.

Healthy Gross Margins

Robust gross margins point to effective product pricing, formulation value and controlled COGS in skincare and healthcare products. Persistent margin strength supports reinvestment in product development and marketing, and gives room to absorb SG&A while targeting a return to net profitability.

Diversified Revenue Streams & Channels

Multiple product lines and distribution channels reduce single-point concentration risk and help stabilize revenues across retail, clinic and online demand cycles. This structural diversification supports market penetration, cross-selling and resilience versus shifts in any single channel.

Negative Factors

Net Losses Affecting Profitability

A reported net loss undermines retained earnings and returns metrics, constraining the company's ability to self-fund growth or pay dividends. Prolonged losses can erode stakeholder confidence, limit strategic options, and require sustained improvement in operating efficiency to restore durable profitability.

Rising Financial Leverage

Increased leverage raises fixed interest obligations and reduces financial flexibility. With higher debt levels, the company faces greater refinancing and interest-rate risk, which can strain cash flow during downturns and limit investments in R&D, marketing or working capital needed for long-term growth.

Weak Cash Flow Conversion

Negative operating and free cash flow signal difficulty converting revenues into sustainable cash, jeopardizing liquidity and day-to-day operations. Persistent weak cash generation forces reliance on external financing, increasing cost of capital and potentially constraining long-term strategic initiatives.

Liberta Co., Ltd. Business Overview & Revenue Model

Company Description

Liberta Co., Ltd. (4935) is a Japanese company primarily engaged in the development, manufacturing, and sale of healthcare products, focusing on innovative solutions for skin health and personal care. The company operates in the pharmaceutical and cosmetic sectors, providing a range of products that include topical treatments, skincare formulations, and health supplements. Liberta is committed to leveraging advanced research and technology to enhance consumer well-being and promote healthier skin.

How the Company Makes Money

Liberta Co., Ltd. generates revenue through multiple streams, primarily from the sale of its skincare and healthcare products. The company distributes its products through various channels, including pharmacies, online platforms, and direct sales, catering to both individual consumers and healthcare professionals. Key revenue streams include prescription medications, over-the-counter skincare products, and health supplements. Additionally, Liberta may engage in strategic partnerships with healthcare providers, clinics, and distributors to expand its market reach and enhance its product offerings, contributing to its overall earnings.

Liberta Co., Ltd. Financial Statement Overview

Summary

Liberta Co., Ltd. has shown strong revenue growth but is facing profitability challenges with a net loss in 2024. The balance sheet indicates increased leverage, and cash flow issues suggest potential liquidity concerns. Improvement in operational efficiency and cash flow management is needed.

Income Statement

Liberta Co., Ltd. showed solid revenue growth from 2023 to 2024 with a revenue increase of approximately 21.8%. Gross profit margins are healthy, but the company posted a net loss in 2024, impacting its net profit margin significantly. EBIT and EBITDA margins are relatively low, indicating potential challenges in operational efficiency.

Balance Sheet

The company's debt-to-equity ratio increased due to rising debt levels, indicating higher financial leverage. Return on equity has been impacted by negative net income in 2024. The equity ratio remains stable, showing a decent proportion of assets financed by equity.

Cash Flow

Liberta Co., Ltd. experienced negative free cash flow growth and negative operating cash flow in 2024, raising concerns about cash management. The operating cash flow to net income ratio is negative, highlighting the issues with converting income into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	8.66B	8.64B	7.09B	6.64B	5.03B	5.11B
Gross Profit	3.55B	3.34B	2.85B	2.60B	2.15B	2.18B
EBITDA	108.18M	259.90M	318.19M	308.32M	286.75M	284.08M
Net Income	-160.41M	-21.17M	111.33M	114.51M	200.23M	155.23M
Balance Sheet
Total Assets	6.95B	6.44B	5.52B	5.31B	2.94B	3.18B
Cash, Cash Equivalents and Short-Term Investments	1.24B	1.01B	880.52M	986.20M	947.59M	959.48M
Total Debt	3.85B	3.44B	2.49B	2.44B	825.45M	1.19B
Total Liabilities	5.61B	4.87B	3.88B	3.74B	1.62B	2.01B
Stockholders Equity	1.33B	1.57B	1.63B	1.57B	1.32B	1.16B
Cash Flow
Free Cash Flow	0.00	-624.92M	311.02M	-825.23M	391.70M	-156.13M
Operating Cash Flow	0.00	-577.34M	414.13M	-799.26M	416.57M	-150.71M
Investing Cash Flow	0.00	-202.74M	-144.96M	-692.94M	-51.12M	-26.93M
Financing Cash Flow	0.00	885.84M	-400.30M	1.51B	-410.29M	419.08M

Liberta Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1875.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4935, the sentiment is Negative. The current price of 1875 is above the 20-day moving average (MA) of 339.33, above the 50-day MA of 364.81, and above the 200-day MA of 389.43, indicating a bearish trend. The MACD of -12.84 indicates Negative momentum. The RSI at 46.34 is Neutral, neither overbought nor oversold. The STOCH value of 45.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4935.

Liberta Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4932	68 Neutral	¥11.46B	36.97	―	5.92%	22.86%	-32.11%
4923	66 Neutral	¥34.14B	24.48	―	1.81%	0.22%	4.15%
4936	63 Neutral	¥9.69B	25.52	―	2.65%	11.87%	-31.02%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
4926	58 Neutral	¥5.33B	17.04	―	1.68%	8.46%	―
4934	52 Neutral	¥6.21B	13.45	―	―	-19.42%	―
4935	49 Neutral	¥9.77B	-70.84	―	0.48%	10.13%	-14654.18%